FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.
Also in this 8-page Issue: Safety Warnings Are Added to Labels for Epo and Avastin.
Cancer Accounts for 23% of U.S. Deaths, American Cancer Society Says.
NCI Sets its Targets for Grant Success Rate and R01 Payline for FY05.
NIH Panel Calls for Further Research On End-of-Life Issues.
NAS Committee Urges Greater Rewards For Interdisciplinary Research.
CAM Therapies Should Be Held to Conventional Standards and Congress Should Toughen Dietary Supplements Act, IOM Panel Says.
Funding Opportunities Listed.
Trending Stories
- With five-year cancer survival at an all-time high, does this mean people are living longer?
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - House passes three-year extension of ACA subsidies with bipartisan support
- When “safe and effective” is not “reasonable and necessary”
We can curb excessive drug dosing and improve the quality of cancer care
